Blurbs

Analysts’ Top Healthcare Picks: Biogen (BIIB), HCA Healthcare (HCA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIBResearch Report) and HCA Healthcare (HCAResearch Report) with bullish sentiments.

Biogen (BIIB)

In a report released yesterday, Michael Yee from Jefferies reiterated a Buy rating on Biogen, with a price target of $300.00. The company’s shares closed last Tuesday at $197.79, close to its 52-week low of $187.16.

According to TipRanks.com, Yee is a 1-star analyst with an average return of -3.5% and a 37.5% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Immunocore Holdings, and Denali Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $263.44 average price target, implying a 33.7% upside from current levels. In a report released yesterday, Mizuho Securities also upgraded the stock to Buy with a $270.00 price target.

See today’s best-performing stocks on TipRanks >>

HCA Healthcare (HCA)

Jefferies analyst Brian Tanquilut maintained a Buy rating on HCA Healthcare yesterday and set a price target of $275.00. The company’s shares closed last Tuesday at $184.31.

According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of 4.5% and a 51.5% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Oncology Institute, Inc., and Hanger Orthopedic.

Currently, the analyst consensus on HCA Healthcare is a Strong Buy with an average price target of $235.00, a 24.1% upside from current levels. In a report issued on September 16, Raymond James also maintained a Buy rating on the stock with a $250.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BIIB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos